FDA Embraces AI: How Public Healthcare Innovators Are Advancing Medical Technology

Behind the FDA's AI Push: A Growing Class of Public Healthcare Innovators

The U.S. Food and Drug Administration (FDA) has fully integrated artificial intelligence (AI) into its internal workflows after a successful trial of a generative AI tool designed to streamline scientific review. This AI system assists experts by reducing time spent on repetitive tasks, signaling a clear shift toward automation in regulatory processes. Analysts highlight this move as confirmation of AI’s expanding role in healthcare, with projections from MarketsandMarkets estimating the AI healthcare market to grow at a 38.6% CAGR, exceeding $110 billion by 2030.

Public Companies Advancing Healthcare AI

As the FDA adopts AI, several public companies are pushing forward with their own AI healthcare platforms. Notable names include Avant Technologies, Inc. (OTCQB: AVAI), RadNet, Inc. (NASDAQ: RDNT), iCad, Inc. (NASDAQ: ICAD), Microsoft Corporation (NASDAQ: MSFT), and HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF). Investment in this sector remains strong, exemplified by Persivia’s recent $107 million funding round to expand its AI-powered platform. By 2035, AI could contribute an estimated $461 billion to a global healthcare system projected to surpass $2.26 trillion.

Avant Technologies and Ainnova Tech Move Toward Merger

Avant Technologies is advancing its AI healthcare footprint through a proposed acquisition of its joint venture partner Ainnova Tech. The companies, collaborating under Ai-nova Acquisition Corp. (AAC), are negotiating a merger ahead of an FDA pre-submission meeting scheduled for July. This consolidation aims to streamline regulatory efforts, clinical trials, and commercial strategies in preparation for entry into the U.S. market.

Vinicio Vargas, CEO of Ainnova, emphasized the benefits: "Bringing the two companies together will simplify the process of advancing our technology to market and deliver value to our customers and partners globally."

The merged entity will hold global rights to Vision AI, a non-invasive clinical screening platform that combines retinal imaging, vital sign capture, and proprietary algorithms. Vision AI detects early signs of diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes. Research cited by the NIH reports AI tools like Vision AI have shown over 90% sensitivity in detecting these conditions before symptoms appear.

Vargas explained, "Our strategy includes rapid deployment in markets with lower regulatory barriers, where Vision AI operates as a screening tool, while simultaneously progressing toward FDA clearance in the U.S. Early regulatory engagement will facilitate faster, credible market entry."

Currently, Vision AI is active in pilot programs across Latin America, including Chile, Mexico, and Brazil, generating real-world data and validating its use in clinical settings. AAC recently enhanced the platform with four new diagnostic algorithms trained on over 2.3 million clinical cases, expanding its ability to detect a wider range of chronic conditions.

RadNet and iCad Announce Merger to Strengthen AI-Powered Breast Cancer Detection

RadNet and iCad have signed a definitive all-stock merger agreement valued at approximately $103 million. This union will combine iCad’s ProFound Breast Health Suite and its extensive global customer base with RadNet’s DeepHealth AI breast screening solutions.

Dr. Howard Berger, RadNet’s President and CEO, stated, "This combination is expected to accelerate our global leadership in AI-powered breast cancer screening, enabling improved accuracy and early detection."

The merger aims to enhance early detection tools and streamline workflow for radiologists. Closing is expected by Q3 2025, pending regulatory approvals.

iCad’s CEO, Dana Brown, highlighted the partnership’s potential: "Together with RadNet, we will broaden access to advanced AI tools, accelerate innovation, and empower radiologists with precise, efficient solutions to improve patient outcomes."

iCad Teams Up with Microsoft to Expand AI Mammography Access

In addition to the RadNet merger, iCad has partnered with Microsoft to offer the ProFound Breast Health Suite via Microsoft's Precision Imaging Network. The platform integrates with PowerScribe, a widely used AI-driven reporting tool among U.S. radiologists. This collaboration opens access to iCad’s mammography solutions in over 17,000 healthcare facilities, providing real-time insights and streamlined workflows.

Vikram Chhabra, General Manager of Diagnostic Solutions at Microsoft, explained, "Integrating iCad’s breast health offerings with our imaging network enhances accuracy and operational efficiency for radiologists."

Microsoft has spotlighted AI's role in healthcare through tools that reduce clinician burnout, improve diagnostics, and personalize treatment. Their multimodal AI models enable faster disease detection and natural language interaction with imaging data, leveraging Azure and Microsoft Fabric platforms.

HEALWELL AI Expands Global Reach with Orion Health Acquisition

HEALWELL AI recently acquired Orion Health, significantly broadening its presence in the public healthcare sector. Orion’s platform supports over 150 million patient lives across 11 countries, bringing a strong enterprise customer base and recurring revenues.

Dr. Alexander Dobranowski, HEALWELL’s CEO, said, "This acquisition strengthens our position with government partners and provides a new channel for distributing our AI products."

The combined company is now positioned to deliver actionable AI-driven insights, accelerate innovation, and unlock additional revenue streams in population health management.

Conclusion

The FDA’s adoption of AI tools signals a shift toward automation in healthcare regulation, reflecting wider industry trends. Public companies like Avant Technologies, RadNet, iCad, Microsoft, and HEALWELL AI are actively advancing AI applications that improve early detection, screening, and healthcare data interoperability. These developments illustrate AI’s growing impact on clinical workflows, regulatory processes, and patient outcomes.

Healthcare professionals interested in expanding their AI knowledge and skills may find valuable resources at Complete AI Training, which offers courses tailored to healthcare and AI integration.